Details of the Drug
General Information of Drug (ID: DMYTUNE)
Drug Name |
5-AMINO-NAPHTALENE-2-MONOSULFONATE
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
119-79-9; 5-Amino-2-naphthalenesulfonic acid; 5-aminonaphthalene-2-sulfonic acid; 1,6-Cleve's acid; 1-Aminonaphthalene-6-sulfonic acid; 2-Naphthalenesulfonic acid, 5-amino-; 1-NAPHTHYLAMINE-6-SULFONIC ACID; Kyselina cleve; 1-Amino-6-naphthalenesulfonic acid; 5-Aminonaphthalene-2-sulphonic acid; Cleve's acid-1,6; 5-Naphthylamine-2-sulfonic acid; 1-Amino-6-sulfonaphthalene; Cleve's beta-acid; Cleve's acid, mixed; Kyselina cleve [Czech]; Kyselina 1-naftylamin-6-sulfonova; 51548-48-2; NSC 31506; UNII-59G56TB11B; Cleve's .beta.-aci
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 223.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -0.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||